HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery
A Phase I/IIa, Open-Label, Dose Escalation Study to Evaluate the Safety and Tolerability of HiCM-188, an Allogeneic iPSC-derived Cardiomyocyte Therapy, in Adult Patients With Advanced Heart Failure
This clinical study will evaluate the safety and tolerability of HiCM-188, an investigational allogeneic induced pluripotent stem cell (iPSC)-derived cardiomyocyte therapy, in adults with advanced heart failure who are undergoing coronary artery bypass grafting (CABG) surgery.
Participants who meet the study eligibility criteria will receive a single dose intramyocardial injection of HiCM-188 during CABG surgery. The study will evaluate two dose levels of HiCM-188 using an open-label dose-escalation design. Participants will be followed for up to 12 months after treatment to monitor safety and preliminary signs of clinical effect.
연구 개요
상세 설명
This is a Phase I/IIa, open-label, dose-escalation study of HiCM-188 in adult participants with advanced heart failure. HiCM-188 is an investigational cell therapy product consisting of allogeneic human iPSC-derived cardiomyocytes intended for intramyocardial administration.
Eligible participants will receive HiCM-188 during coronary artery bypass grafting (CABG) surgery. The study uses a 3+3 dose-escalation design to evaluate two dose levels of HiCM-188: 0.5 × 10^8 cells and 1.5 × 10^8 cells. The primary objective is to evaluate the safety and tolerability of intramyocardial injection of HiCM-188. Secondary objectives include evaluation of preliminary efficacy based on cardiac function, myocardial perfusion, exercise capacity, NYHA functional classification, quality of life, and major adverse cardiac events.
Participants will be monitored during the in-hospital period after CABG surgery and HiCM-188 administration, and then followed for up to 12 months after treatment.
연구 유형
등록 (추정된)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Alex Zhang
- 전화번호: +1 650 504 5586
- 이메일: Alex.zhang@helptx.com.cn
연구 장소
-
-
Texas
-
Houston, Texas, 미국, 77030
- The Texas Heart Institute at Baylor College of Medicine
-
수석 연구원:
- Emerson Perin
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Able to sign informed consent and comply with the study protocol
- 18 to 75 years old at the time of signing informed consent
- Advanced heart failure patients with New York Heart Association (NYHA) class III to IVa despite receiving guideline-directed medical therapy (GDMT)
- Patients with an indication for coronary artery bypass grafting (CABG) per 2011 ACCF/AHA Guideline meeting a Class of Recommendation (COR) of Class I or Class IIa
- Minimum left ventricular wall thickness of ≥ 8 mm in the areas of injection, as confirmed on the screening echocardiogram (ECHO) or cardiac MRI
- Left ventricular ejection fraction (LVEF) of 20% to 45%, as confirmed on the screening echocardiogram (ECHO) or cardiac MRI
- Other criteria apply. Please contact the investigator for more information.
Exclusion Criteria:
- Viral myocarditis
- Amyloidosis
- Pericardial disorders or pericarditis
- Left ventricular aneurysm or thrombus, except a small laminar thrombus at the site of previous myocardial infarction (MI) in a different area
- Primary significant organic valvular heart disease, with specified dimensions
- Untreated congenital heart disease
- Complete atrioventricular (AV) conduction block
- History of left ventricular assist device surgery
- Other criteria apply. Please contact the investigator for more information.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: HiCM-188 Low Dose
Participants in this arm will receive a single low dose of HiCM-188, 0.5 × 10^8 cells, administered by intramyocardial injection during coronary artery bypass grafting (CABG) surgery.
|
HiCM-188 is an investigational allogeneic human induced pluripotent stem cell (iPSC)-derived cardiomyocyte therapy administered as intramyocardial injection during CABG surgery.
|
|
실험적: HiCM-188 High Dose
Participants in this arm will receive a single high dose of HiCM-188, 1.5 × 10^8 cells, administered by intramyocardial injection during coronary artery bypass grafting (CABG) surgery.
|
HiCM-188 is an investigational allogeneic human induced pluripotent stem cell (iPSC)-derived cardiomyocyte therapy administered as intramyocardial injection during CABG surgery.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of Serious Adverse Events
기간: Up to 12 months post-transplant
|
Incidence of serious adverse events (SAEs) at 12 months post-transplant
|
Up to 12 months post-transplant
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change From Baseline in Left Ventricular Ejection Fraction by Cardiac MRI
기간: Baseline, 6 months, and 12 months
|
Change from baseline in left ventricular ejection fraction (LVEF, %) assessed by cardiac magnetic resonance imaging (MRI).
Echocardiogram may be used as an alternative if cardiac MRI is not medically appropriate or per institutional practice.
|
Baseline, 6 months, and 12 months
|
|
Change From Baseline in Left Ventricular End-Diastolic Volume by Cardiac MRI
기간: Baseline, 6 months, and 12 months
|
Change from baseline in left ventricular end-diastolic volume (LVEDV, mL) assessed by cardiac MRI.
Echocardiogram may be used as an alternative if cardiac MRI is not medically appropriate or per institutional practice.
|
Baseline, 6 months, and 12 months
|
|
Change From Baseline in Left Ventricular End-Systolic Volume by Cardiac MRI
기간: Baseline, 6 months, and 12 months
|
Change from baseline in left ventricular end-systolic volume (LVESV, mL) assessed by cardiac MRI.
Echocardiogram may be used as an alternative if cardiac MRI is not medically appropriate or per institutional practice.
|
Baseline, 6 months, and 12 months
|
|
Change From Baseline in Infarct Size by Cardiac MRI
기간: Baseline, 6 months, and 12 months
|
Change from baseline in myocardial infarct size assessed by cardiac MRI.
|
Baseline, 6 months, and 12 months
|
|
Change From Baseline in Myocardial Tissue Perfusion by PET/CT or SPECT
기간: Baseline, 6 months, and 12 months
|
Change from baseline in myocardial tissue perfusion assessed by positron emission tomography/computed tomography (PET/CT) or single-photon emission computed tomography (SPECT).
|
Baseline, 6 months, and 12 months
|
|
Incidence of Major Adverse Cardiac Events
기간: Up to 12 months post-transplant
|
Incidence of major adverse cardiac events (MACE) during the study follow-up period.
|
Up to 12 months post-transplant
|
|
Change From Baseline in 6-Minute Walk Distance
기간: Baseline, 6 months, and 12 months
|
Change from baseline in exercise capacity as assessed by the 6-minute walk distance (6MWD).
The 6-Minute Walk Distance is measured as the distance walked in 6 minutes, with longer distances reflecting better functional exercise capacity.
|
Baseline, 6 months, and 12 months
|
|
Change From Baseline in New York Heart Association Functional Classification
기간: Baseline, 6 months, and 12 months
|
Change from baseline in New York Heart Association (NYHA) functional classification.
The New York Heart Association Functional Classification ranges from Class I to Class IV, with higher classes reflecting more severe limitation of physical activity and worse heart failure symptoms.
|
Baseline, 6 months, and 12 months
|
|
Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score
기간: Baseline, 6 months, and 12 months
|
Change from baseline in quality of life as measured by the Minnesota Living with Heart Failure Questionnaire (MLHFQ).
The Minnesota Living With Heart Failure Questionnaire score ranges from 0 to 105, with higher scores reflecting worse heart failure-related quality of life.
|
Baseline, 6 months, and 12 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
- HICM188H1101
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .